XM does not provide services to residents of the United States of America.
G
G

Gilead

News

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda

UPDATE 1-Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Adds details in paragraph 2, background in paragraphs 4-6 Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus outbreak.
G

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak. Reporting by Mariam Sunny in Bengaluru' Editing by A
G

Gilead Donates About 5,000 Vials Of Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda

BRIEF-Gilead Donates About 5,000 Vials Of Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda Oct 3 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD DONATES REMDESIVIR FOR EMERGENCY USE IN RESPONSE TO MARBURG VIRUS DISEASE IN RWANDA GILEAD - IT WILL DONATE APPROXIMATELY 5,000 VIALS OF REMDESIVIR TO RWANDA MEDICAL SUPPLY Furth
G

Rwanda to start vaccine trials for Marburg disease in a few weeks

UPDATE 3-Rwanda to start vaccine trials for Marburg disease in a few weeks Adds detail from WHO in paragraphs 5-6, 8 By Philbert Girinema KIGALI, Oct 3 (Reuters) - Rwanda w ill start cinical trials of experimental vaccines and t reatments f or Marburg disease in the next few weeks , its health minister said on Thursday, t o fight the country's first outbreak of the viral fever, which has so far killed 11 people .
G

New York Times business news - Oct 3

PRESS DIGEST- New York Times business news - Oct 3 Oct 3 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - OpenAI, the company behind ChatGPT, said it had completed a $6.6 billion fund-raising deal that nearly doubles the high-profile company's valuation from just nine months ago.
G
M

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.